Daratumumab Biosimilar(Rophibio)

N/A

Report date: 2024/07/31 15:37:50

Base Information

Drug NameDaratumumab Biosimilar(Rophibio)

Drug Alias NameRBS-005

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionAnti-CD38Antibody-dependent cell-mediated cytotoxicity (ADCC) effects

TargetsLymphocyte differentiation antigen CD38

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRophibio Inc

China Registration ClassN/A

Active CompaniesRophibio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeL01FC01L01XC24